ES3060110T3 - Formulation for anti-alpha4beta7 antibody - Google Patents

Formulation for anti-alpha4beta7 antibody

Info

Publication number
ES3060110T3
ES3060110T3 ES24167554T ES24167554T ES3060110T3 ES 3060110 T3 ES3060110 T3 ES 3060110T3 ES 24167554 T ES24167554 T ES 24167554T ES 24167554 T ES24167554 T ES 24167554T ES 3060110 T3 ES3060110 T3 ES 3060110T3
Authority
ES
Spain
Prior art keywords
antibody
formulations
formulation
antioxidant
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES24167554T
Other languages
Spanish (es)
Inventor
Willow Diluzio
Phuong M Nguyen
Csanad M Varga
Vaithianathan Palaniappan
Jason Brown
Irving H Fox
Catherine Scholz
Erica Helen Jenkins
Maria Rosario
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3060110T3 publication Critical patent/ES3060110T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen formulaciones de anticuerpos que comprenden una mezcla de un anticuerpo anti-α4β7, un antioxidante o quelante y al menos un aminoácido libre. Estas formulaciones pueden presentar mayor estabilidad, menor formación de agregados o ambas. La presente invención proporciona, además, un régimen de dosificación seguro y fácil de seguir para estas formulaciones de anticuerpos, que da como resultado una cantidad terapéuticamente eficaz del anticuerpo anti-α4β7 in vivo. (Traducción automática con Google Translate, sin valor legal)Antibody formulations comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelating agent, and at least one free amino acid are described. These formulations may exhibit greater stability, less aggregate formation, or both. The present invention further provides a safe and easy-to-follow dosing regimen for these antibody formulations, resulting in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

ES24167554T 2011-05-02 2012-05-02 Formulation for anti-alpha4beta7 antibody Active ES3060110T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161481522P 2011-05-02 2011-05-02

Publications (1)

Publication Number Publication Date
ES3060110T3 true ES3060110T3 (en) 2026-03-25

Family

ID=57792056

Family Applications (1)

Application Number Title Priority Date Filing Date
ES24167554T Active ES3060110T3 (en) 2011-05-02 2012-05-02 Formulation for anti-alpha4beta7 antibody

Country Status (3)

Country Link
AR (1) AR122749A2 (en)
ES (1) ES3060110T3 (en)
UA (1) UA112984C2 (en)

Also Published As

Publication number Publication date
UA112984C2 (en) 2016-11-25
AR122749A2 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
DOP2013000252A (en) FORMULATION FOR ANTIBODY ANTI-a4ß7
DOP2013000253A (en) FORMULATION FOR ANTIBODY ANTI-a4ß7
GT201400285A (en) FORMULATION OF ANTIBODIES
ECSP11010869A (en) PHARMACEUTICAL COMBINATION 3- (3-DIMETHYLAMINE-1-ETIL-2-METHYL-PROPIL) -PHENOL AND AN ANTIEPILEPTIC
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
CR10975A (en) FORMULATIONS FOR CANCER TREATMENT
NZ709958A (en) Enhanced stability of novel liquid compositions
CL2012002551A1 (en) Pharmaceutical combination comprising at least one 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol of formula (i) and at least one nmda antagonist; pharmaceutical composition; and use for pain treatment.
ECSP14033371A (en) PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS
UY32520A (en) COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
CO6280503A2 (en) NEURTURINE CONJUGATES NEW FOR PHARMACEUTICAL USE
BR112015018200A2 (en) chewable composition for oral administration and process for preparing same
BR112013028772A2 (en) veterinary composition for intramammary administration, and kit
ES3060110T3 (en) Formulation for anti-alpha4beta7 antibody
CR20120465A (en) IMPROVED FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY
TN2013000455A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY